Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)
Thomas Cerny(Kantonsspital St. Gallen), S.B. Kaye(University of Bern), N. Pavlidis, Ron Epelbaum(University of Bern), J Van Meerbeek(University of Bern), Steven Kaplan(Kantonsspital Baselland), H. R. Franklin(European Organisation for Research and Treatment of Cancer), J. Wanders(Eisai (United Kingdom)), Patrick Schöffski(KU Leuven)
Cited by 161
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k